A carcinoma that arises from the common bile duct distal to the insertion of the cystic duct.
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation surrounding distal biliary tract carcinoma is limited primarily due to its rarity, which affects fewer than 5,000 people annually in the U.S. This low prevalence results in fewer systematic clinical studies and a lack of comprehensive data on genetic factors and phenotypic features. As research continues to evolve, there is hope for better understanding and management of this condition.
To navigate your care for distal biliary tract carcinoma, seek out an oncologist with expertise in biliary cancers. It is also beneficial to connect with clinical trial coordinators who can provide information on ongoing research studies. Resources like the National Cancer Institute (cancer.gov) offer valuable information on treatment options and support. Consider participating in clinical trials, as they may provide access to cutting-edge therapies. Additionally, inquire about any available patient registries or natural history studies that can contribute to a better understanding of the disease.
Currently, there are two orphan drug designations for distal biliary tract carcinoma. Pembrolizumab is an FDA-approved treatment, while Cis-diamminedichloroplatinum (II) polyethylene glycol-polyglutamate is in development. There are also six active clinical trials exploring various treatment options. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=distal%20biliary%20tract%20carcinoma.
Actionable guidance for navigating care for distal biliary tract carcinoma
To navigate your care for distal biliary tract carcinoma, seek out an oncologist with expertise in biliary cancers. It is also beneficial to connect with clinical trial coordinators who can provide information on ongoing research studies. Resources like the National Cancer Institute (cancer.gov) offer valuable information on treatment options and support. Consider participating in clinical trials, as they may provide access to cutting-edge therapies. Additionally, inquire about any available patient registries or natural history studies that can contribute to a better understanding of the disease.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding distal biliary tract carcinoma is limited primarily due to its rarity, which affects fewer than 5,000 people annually in the U.S. This low prevalence results in fewer systematic clinical studies and a lack of comprehensive data on genetic factors and phenotypic features. As research continues to evolve, there is hope for better understanding and management of this condition.
To navigate your care for distal biliary tract carcinoma, seek out an oncologist with expertise in biliary cancers. It is also beneficial to connect with clinical trial coordinators who can provide information on ongoing research studies. Resources like the National Cancer Institute (cancer.gov) offer valuable information on treatment options and support. Consider participating in clinical trials, as they may provide access to cutting-edge therapies. Additionally, inquire about any available patient registries or natural history studies that can contribute to a better understanding of the disease.
Currently, there are two orphan drug designations for distal biliary tract carcinoma. Pembrolizumab is an FDA-approved treatment, while Cis-diamminedichloroplatinum (II) polyethylene glycol-polyglutamate is in development. There are also six active clinical trials exploring various treatment options. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=distal%20biliary%20tract%20carcinoma.
Actionable guidance for navigating care for distal biliary tract carcinoma
To navigate your care for distal biliary tract carcinoma, seek out an oncologist with expertise in biliary cancers. It is also beneficial to connect with clinical trial coordinators who can provide information on ongoing research studies. Resources like the National Cancer Institute (cancer.gov) offer valuable information on treatment options and support. Consider participating in clinical trials, as they may provide access to cutting-edge therapies. Additionally, inquire about any available patient registries or natural history studies that can contribute to a better understanding of the disease.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding distal biliary tract carcinoma is limited primarily due to its rarity, which affects fewer than 5,000 people annually in the U.S. This low prevalence results in fewer systematic clinical studies and a lack of comprehensive data on genetic factors and phenotypic features. As research continues to evolve, there is hope for better understanding and management of this condition.
To navigate your care for distal biliary tract carcinoma, seek out an oncologist with expertise in biliary cancers. It is also beneficial to connect with clinical trial coordinators who can provide information on ongoing research studies. Resources like the National Cancer Institute (cancer.gov) offer valuable information on treatment options and support. Consider participating in clinical trials, as they may provide access to cutting-edge therapies. Additionally, inquire about any available patient registries or natural history studies that can contribute to a better understanding of the disease.
Currently, there are two orphan drug designations for distal biliary tract carcinoma. Pembrolizumab is an FDA-approved treatment, while Cis-diamminedichloroplatinum (II) polyethylene glycol-polyglutamate is in development. There are also six active clinical trials exploring various treatment options. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=distal%20biliary%20tract%20carcinoma.
Actionable guidance for navigating care for distal biliary tract carcinoma
To navigate your care for distal biliary tract carcinoma, seek out an oncologist with expertise in biliary cancers. It is also beneficial to connect with clinical trial coordinators who can provide information on ongoing research studies. Resources like the National Cancer Institute (cancer.gov) offer valuable information on treatment options and support. Consider participating in clinical trials, as they may provide access to cutting-edge therapies. Additionally, inquire about any available patient registries or natural history studies that can contribute to a better understanding of the disease.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 4 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.